About Enoyl-[acyl-carrier-protein] reductase, mitochondrial
Enoyl-[acyl-carrier-protein] reductase, mitochondrial (MECR) is a protein
from Homo sapiens identified by UniProt accession
Q9BV79, 373 residues long.
MolForge cross-references it against 0 known binders and
55 disease associations.
Target properties
| Protein name | Enoyl-[acyl-carrier-protein] reductase, mitochondrial |
| UniProt accession | Q9BV79 |
| Gene | MECR |
| Organism | Homo sapiens |
| Length | 373 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (55)
Diseases linked to this target (Open Targets).
- dystonia, childhood-onset, with optic atrophy and basal ganglia abnormalities · score 0.78
- neurodegenerative disease · score 0.45
- optic atrophy · score 0.39
- mitochondrial disease · score 0.33
- genetic disorder · score 0.19
- Leigh syndrome · score 0.18
- diastolic blood pressure · score 0.11
- wellbeing measurement · score 0.11
- alcohol consumption measurement · score 0.11
- adolescent idiopathic scoliosis · score 0.10
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q9BV79-F1 | alphafold | PREDICTED | 90.52 | — |
Amino-acid sequence (373 residues)
MWVCSTLWRV RTPARQWRGL LPASGCHGPA ASSYSASAEP ARVRALVYGH HGDPAKVVEL KNLELAAVRG SDVRVKMLAA PINPSDINMI QGNYGFLPEL PAVGGNEGVA QVVAVGSNVT GLKPGDWVIP ANAGLGTWRT EAVFSEEALI QVPSDIPLQS AATLGVNPCT AYRMLMDFEQ LQPGDSVIQN ASNSGVGQAV IQIAAALGLR TINVVRDRPD IQKLSDRLKS LGAEHVITEE ELRRPEMKNF FKDMPQPRLA LNCVGGKSST ELLRQLARGG TMVTYGGMAK QPVVASVSLL IFKDLKLRGF WLSQWKKDHS PDQFKELILT LCDLIRRGQL TAPACSQVPL QDYQSALEAS MKPFISSKQI LTM
Explore Enoyl-[acyl-carrier-protein] reductase, mitochondrial with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets